---
layout: post
title: "Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium Avium Complex: Developing Drugs for Treatment; Guidance for Industry; Availability"
date: 2026-02-05 18:56:42 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2023-19060
original_published: 2023-09-05 00:00:00 +0000
significance: 8.00
---

# Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium Avium Complex: Developing Drugs for Treatment; Guidance for Industry; Availability

**Published:** February 05, 2026 18:56 UTC
**Source:** Federal Register
**Original Published:** September 05, 2023 00:00 UTC
**Document Number:** 2023-19060

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex: Developing Drugs for Treatment." This guidance assists sponsors in the clinical development of drugs for the treatment of nontuberculous mycobacterial pulmonary disease (NTM-PD) caused by Mycobacterium avium complex (MAC). This guidance finalizes the draft guidance of the same title issued on September 29, 2021.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2023/09/05/2023-19060/nontuberculous-mycobacterial-pulmonary-disease-caused-by-mycobacterium-avium-complex-developing)
- API: https://www.federalregister.gov/api/v1/documents/2023-19060

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
